Abstract Title:

[The use of hepatoprotector LiverPro in combined therapy of chronic viral hepatitis C].

Abstract Source:

Klin Med (Mosk). 2008;86(11):60-2. PMID: 19177797

Abstract Author(s):

Iu V Tel'nykh, M V Maevskaia, D V Glushenkov


We analysed clinical characteristics, laboratory findings, nature and frequency of side effects, and positive virologic response rate in 20 patients with chronic viral hepatitis C (HCV) given combined antiviral therapy with PEG-Intron, ribavirin, and LiverPro hepatoprotector (Santegra, USA, two capsules twice daily) during 3 months. The results were compared with those obtained in the control group of HCV patients receiving the same treatment excepting the hepatoprotector. Clinical manifestations of HCV in the former group disappeared 7-10 days earlier than in control. Also, cytolytic syndrome resolved in these patients, the positive virologic response rate was 20% higher and the frequency of severe side effects of interferon therapy that required its withdrawal was 10% lower. The authors recommend to include LiverPro in combined therapy of HCV.

Study Type : Human Study

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.